CBDX (Curative Biosciences) Liabilities-to-Assets : 51.43 (As of Mar. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Curative Biosciences Liabilities-to-Assets?

Curative Biosciences CBDX Liabilities-to-Assets is 51.43 as of Mar. 2018.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Curative Biosciences's Total Liabilities for the quarter that ended in Mar. 2018 was $0.72 Mil. Curative Biosciences's Total Assets for the quarter that ended in Mar. 2018 was $0.01 Mil. Therefore, Curative Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2018 was 51.43.

Curative Biosciences  (OTCPK:CBDX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Curative Biosciences Liabilities-to-Assets Related Terms

Curative Biosciences Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Curative Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences Liabilities-to-Assets Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.64 23.81 70.60 124.00 316.50

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 205.33 316.50 324.50 675.00 51.43

CBDX vs ACUR, CVLB, RDGL: Liabilities-to-Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curative Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biosciences Liabilities-to-Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curative Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Curative Biosciences's Liabilities-to-Assets falls into.


Curative Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Curative Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2017 is calculated as:

Liabilities-to-Assets (A: Jun. 2017 )=Total Liabilities/Total Assets
=0.633/0.002
=316.50

Curative Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2018 is calculated as

Liabilities-to-Assets (Q: Mar. 2018 )=Total Liabilities/Total Assets
=0.72/0.014
=51.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 51.43 mean?
Curative Biosciences (CBDX) has a Liabilities-to-Assets of 51.43 as of Mar. 2018. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Curative Biosciences and its competitors.
Is Curative Biosciences' Liabilities-to-Assets too high?
Curative Biosciences' current Liabilities-to-Assets is 51.43.
How does Curative Biosciences' Liabilities-to-Assets compare to ACUR and CVLB?
Curative Biosciences' Liabilities-to-Assets of 51.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Curative Biosciences and its competitors. Curative Biosciences's current Liabilities-to-Assets is 51.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biosciences stock overvalued right now?
Curative Biosciences (CBDX) has a current Liabilities-to-Assets of 51.43. The current Liabilities-to-Assets is 51.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Curative Biosciences (CBDX), the current Liabilities-to-Assets is 51.43 as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biosciences Business Description

Address 2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.